Annual EBITDA
$65.48 M
+$64.63 M+7630.58%
December 31, 2022
Summary
- As of February 8, 2025, EGRX annual EBITDA is $65.48 million, with the most recent change of +$64.63 million (+7630.58%) on December 31, 2022.
- During the last 3 years, EGRX annual EBITDA has risen by +$37.30 million (+132.39%).
- EGRX annual EBITDA is now -15.87% below its all-time high of $77.83 million, reached on December 31, 2017.
Performance
EGRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$16.33 M
-$981.00 K-5.67%
June 30, 2023
Summary
- As of February 8, 2025, EGRX quarterly EBITDA is $16.33 million, with the most recent change of -$981.00 thousand (-5.67%) on June 30, 2023.
- Over the past year, EGRX quarterly EBITDA has increased by +$20.01 million (+543.40%).
- EGRX quarterly EBITDA is now -72.30% below its all-time high of $58.93 million, reached on March 31, 2022.
Performance
EGRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$56.28 M
+$20.01 M+55.16%
June 30, 2023
Summary
- As of February 8, 2025, EGRX TTM EBITDA is $56.28 million, with the most recent change of +$20.01 million (+55.16%) on June 30, 2023.
- Over the past year, EGRX TTM EBITDA has increased by +$9.70 million (+20.83%).
- EGRX TTM EBITDA is now -40.98% below its all-time high of $95.35 million, reached on September 30, 2017.
Performance
EGRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
EGRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7630.6% | +543.4% | +20.8% |
| 3 y3 years | +132.4% | +132.1% | +511.0% |
| 5 y5 years | -15.9% | +1293.0% | +99.8% |
EGRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +7630.6% | -72.3% | +543.4% | -27.8% | +6544.8% |
| 5 y | 5-year | at high | +7630.6% | -72.3% | +243.7% | -27.8% | +6544.8% |
| alltime | all time | -15.9% | +433.8% | -72.3% | +243.7% | -41.0% | +350.3% |
Eagle Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | $16.33 M(-5.7%) | $56.28 M(+55.2%) |
| Mar 2023 | - | $17.31 M(-17.1%) | $36.27 M(-53.4%) |
| Dec 2022 | $65.48 M(+7630.6%) | $20.87 M(+1072.4%) | $77.90 M(+30.4%) |
| Sep 2022 | - | $1.78 M(-148.3%) | $59.72 M(+28.2%) |
| Jun 2022 | - | -$3.68 M(-106.2%) | $46.58 M(-18.5%) |
| Mar 2022 | - | $58.93 M(+2094.1%) | $57.12 M(+6644.2%) |
| Dec 2021 | $847.00 K(-97.1%) | $2.69 M(-123.6%) | $847.00 K(-92.2%) |
| Sep 2021 | - | -$11.36 M(-265.5%) | $10.84 M(-66.6%) |
| Jun 2021 | - | $6.86 M(+158.2%) | $32.48 M(-0.5%) |
| Mar 2021 | - | $2.66 M(-79.0%) | $32.65 M(+13.4%) |
| Dec 2020 | $28.79 M(+2.2%) | $12.68 M(+23.4%) | $28.79 M(+41.9%) |
| Sep 2020 | - | $10.28 M(+46.1%) | $20.30 M(+120.4%) |
| Jun 2020 | - | $7.04 M(-685.3%) | $9.21 M(-30.1%) |
| Mar 2020 | - | -$1.20 M(-128.7%) | $13.18 M(-53.2%) |
| Dec 2019 | $28.18 M(-30.3%) | $4.19 M(-617.0%) | $28.18 M(-30.7%) |
| Sep 2019 | - | -$810.00 K(-107.4%) | $40.68 M(-33.0%) |
| Jun 2019 | - | $11.00 M(-20.3%) | $60.73 M(+19.3%) |
| Mar 2019 | - | $13.80 M(-17.3%) | $50.90 M(+25.8%) |
| Dec 2018 | $40.44 M(-48.0%) | $16.69 M(-13.3%) | $40.45 M(+14.9%) |
| Sep 2018 | - | $19.25 M(+1542.2%) | $35.20 M(-15.9%) |
| Jun 2018 | - | $1.17 M(-64.9%) | $41.87 M(-12.0%) |
| Mar 2018 | - | $3.34 M(-70.8%) | $47.56 M(-38.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $77.83 M(+41.4%) | $11.44 M(-55.9%) | $77.83 M(-18.4%) |
| Sep 2017 | - | $25.92 M(+277.7%) | $95.35 M(+16.1%) |
| Jun 2017 | - | $6.86 M(-79.6%) | $82.13 M(-8.0%) |
| Mar 2017 | - | $33.61 M(+16.0%) | $89.27 M(+62.2%) |
| Dec 2016 | $55.02 M(+1940.2%) | $28.96 M(+128.0%) | $55.03 M(+101.2%) |
| Sep 2016 | - | $12.70 M(-9.3%) | $27.34 M(+540.1%) |
| Jun 2016 | - | $14.00 M(-2314.9%) | $4.27 M(-123.7%) |
| Mar 2016 | - | -$632.00 K(-149.5%) | -$18.04 M(-768.8%) |
| Dec 2015 | $2.70 M(-114.1%) | $1.28 M(-112.3%) | $2.70 M(-152.6%) |
| Sep 2015 | - | -$10.37 M(+24.7%) | -$5.13 M(+33.6%) |
| Jun 2015 | - | -$8.32 M(-141.4%) | -$3.84 M(-344.2%) |
| Mar 2015 | - | $20.11 M(-407.0%) | $1.57 M(-107.0%) |
| Dec 2014 | - | -$6.55 M(-27.8%) | -$22.49 M(+17.4%) |
| Sep 2014 | -$19.16 M(+254.0%) | -$9.08 M(+212.3%) | -$19.16 M(+100.3%) |
| Jun 2014 | - | -$2.91 M(-26.4%) | -$9.57 M(+76.3%) |
| Mar 2014 | - | -$3.95 M(+22.5%) | -$5.43 M(-6.2%) |
| Dec 2013 | - | -$3.22 M(-728.2%) | -$5.78 M(+6.9%) |
| Sep 2013 | -$5.41 M(-72.4%) | $513.20 K(-58.4%) | -$5.41 M(-8.7%) |
| Jun 2013 | - | $1.23 M(-128.7%) | -$5.93 M(-17.2%) |
| Mar 2013 | - | -$4.31 M(+50.9%) | -$7.16 M(+150.9%) |
| Dec 2012 | - | -$2.85 M | -$2.85 M |
| Sep 2012 | -$19.61 M | - | - |
FAQ
- What is Eagle Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals annual EBITDA year-on-year change?
- What is Eagle Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Eagle Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals TTM EBITDA year-on-year change?
What is Eagle Pharmaceuticals annual EBITDA?
The current annual EBITDA of EGRX is $65.48 M
What is the all time high annual EBITDA for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual EBITDA is $77.83 M
What is Eagle Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, EGRX annual EBITDA has changed by +$64.63 M (+7630.58%)
What is Eagle Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of EGRX is $16.33 M
What is the all time high quarterly EBITDA for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly EBITDA is $58.93 M
What is Eagle Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, EGRX quarterly EBITDA has changed by +$20.01 M (+543.40%)
What is Eagle Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of EGRX is $56.28 M
What is the all time high TTM EBITDA for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high TTM EBITDA is $95.35 M
What is Eagle Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, EGRX TTM EBITDA has changed by +$9.70 M (+20.83%)